Taoweave (TWAV)Director bought ~$13K
Jonathan Schechter, Director at Taoweave, bought ~$13K of Taoweave shares.
- ~$13K
- Approx. value · 5,000 sh @ $2.70
- 15K
- Holds after · shares reported
- Traded
- Sep 17, 2025
- Filed
- Sep 17, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 4, 2025Insider · 1 personInsiders: 5 purchases (~$27K)
- Sep 10, 2025Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news
- Sep 16, 2025Insider · Largest insider buy since 2008Director purchased ~$27K of OBLG shares in the open market
- Sep 17, 2025 · this disclosureInsiderDirector purchased ~$13K of TWAV shares in the open market
What came next
- Nov 13, 2025Company filing · Form 8-K · ResultsReported its results
- Nov 14, 2025Insider · 2 peopleInsiders: 2 purchases (~$38K)
- Nov 19, 2025InsiderCEO purchased ~$9.5K of TWAV shares in the open market
- Dec 2, 2025Company filing · Form 8-K · Bylaws or charter, Reg FDChanged its bylaws, charter or fiscal year, and shared information with investors
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Taoweave
OQRO holds no insider, Congress, fund or contract record for Taoweave dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TWAV page.
Other recent filings by Jonathan Schechter, Director
- SEC Form 4 at Pharmacyte Biotech (PMCB)Jan 7, 2026
- SEC Form 4 at Pharmacyte Biotech (PMCB)Jan 7, 2026
- SEC Form 4 at Pharmacyte Biotech (PMCB)Jan 7, 2026
- SEC Form 4 at Taoweave (TWAV)Nov 17, 2025
- SEC Form 4 at Taoweave (TWAV)Sep 16, 2025
The full history of Jonathan Schechter, Director is on the profile page.
How this filing works
Other disclosures at Taoweave
- SEC Form 4Nov 19, 2025
- SEC Form 4Nov 17, 2025
- SEC Form 4Nov 17, 2025
- SEC Form 4Sep 16, 2025
- SEC Form 4Sep 9, 2025
- SEC Form 4Sep 9, 2025
Everything OQRO holds on this company is on its TWAV page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data